X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ASTRAZENECA PHARMA SUN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 44.7 134.3 33.3% View Chart
P/BV x 3.6 20.4 17.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
ASTRAZENECA PHARMA
Mar-14
SUN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8421,285 65.5%   
Low Rs572634 90.3%   
Sales per share (Unadj.) Rs131.6189.6 69.4%  
Earnings per share (Unadj.) Rs32.7-0.2 -16,062.2%  
Cash flow per share (Unadj.) Rs38.03.8 987.8%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.768.6 222.5%  
Shares outstanding (eoy) m2,399.2625.00 9,597.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.45.1 106.2%   
Avg P/E ratio x21.6-4,712.7 -0.5%  
P/CF ratio (eoy) x18.6249.6 7.5%  
Price / Book Value ratio x4.614.0 33.1%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,87723,988 7,074.0%   
No. of employees `00017.51.6 1,123.5%   
Total wages/salary Rs m49,0231,605 3,055.2%   
Avg. sales/employee Rs Th18,028.33,040.2 593.0%   
Avg. wages/employee Rs Th2,798.81,029.2 271.9%   
Avg. net profit/employee Rs Th4,479.5-3.3 -137,200.1%   
INCOME DATA
Net Sales Rs m315,7844,740 6,662.5%  
Other income Rs m6,23292 6,766.0%   
Total revenues Rs m322,0164,832 6,664.5%   
Gross profit Rs m100,893-130 -77,729.4%  
Depreciation Rs m12,648101 12,497.5%   
Interest Rs m3,9980-   
Profit before tax Rs m90,479-139 -65,139.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m12,1165 238,029.5%   
Profit after tax Rs m78,462-5 -1,541,499.0%  
Gross profit margin %31.9-2.7 -1,166.7%  
Effective tax rate %13.4-3.7 -365.4%   
Net profit margin %24.8-0.1 -23,136.9%  
BALANCE SHEET DATA
Current assets Rs m329,5372,726 12,086.9%   
Current liabilities Rs m178,8702,435 7,345.8%   
Net working cap to sales %47.76.1 776.0%  
Current ratio x1.81.1 164.5%  
Inventory Days Days7974 107.1%  
Debtors Days Days8341 204.2%  
Net fixed assets Rs m204,7661,035 19,778.4%   
Share capital Rs m2,39950 4,798.6%   
"Free" reserves Rs m363,997942 38,624.5%   
Net worth Rs m366,3971,716 21,351.8%   
Long term debt Rs m14,3610-   
Total assets Rs m614,1024,156 14,776.3%  
Interest coverage x23.6NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.51.1 45.1%   
Return on assets %13.4-0.1 -10,963.8%  
Return on equity %21.4-0.3 -7,219.5%  
Return on capital %24.80-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m44,118375 11,777.4%   
Fx outflow Rs m24,484470 5,207.7%   
Net fx Rs m19,634-96 -20,548.4%   
CASH FLOW
From Operations Rs m70,822-8 -874,346.9%  
From Investments Rs m-42,216-146 28,974.6%  
From Financial Activity Rs m-22,854862 -2,650.6%  
Net Cashflow Rs m6,107709 861.9%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 15.7 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 12,856 1,034.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   GSK PHARMA  NATCO PHARMA  BIOCON LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 200 Points; Energy Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in green.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Real Truth About India's FDI, Beyond WhatsApp(Vivek Kaul's Diary)

Jul 4, 2018

The FDI numbers do not look very impressive once we adjust for repatriations as well as the overall growth in the economy.

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 17, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS